New MRI dye could sharpen liver lesion detection

NCT ID NCT06596616

ENROLLING_BY_INVITATION Diagnosis Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new MRI contrast agent, gadopiclenol, to the standard agent, gadoxetate, for imaging liver lesions. Researchers will enroll 23 adults with chronic liver disease or known liver lesions to see if gadopiclenol provides equal or better image quality and lesion visibility. Participants will undergo two MRI scans, one with each agent, and the images will be compared.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gadopiclenol (a gadolinium-based contrast agent for MRI)
What this could lead to: If successful, this could show that gadopiclenol is as good as or better than the current standard for detecting liver lesions, potentially offering a new option for MRI scans.
What could go wrong: This is a small, early-phase study with only 23 participants, so results may not apply to everyone. The study compares image quality, not patient outcomes, and both agents carry a small risk of allergic reaction or kidney issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER LESION

Contacts and locations

Locations

BMEII

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.